Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment

Zhongyi Hu, Junzhi Zhou, Junjie Jiang, Jiao Yuan, Youyou Zhang, Xuepeng Wei, Nicki Loo, Yueying Wang, Yutian Pan, Tianli Zhang, Xiaomin Zhong, Meixiao Long, Kathleen T. Montone, Janos L. Tanyi, Yi Fan, Tian-Li Wang, Ie-Ming Shih, Xiaowen Hu () and Lin Zhang ()
Additional contact information
Zhongyi Hu: University of Pennsylvania
Junzhi Zhou: University of Pennsylvania
Junjie Jiang: University of Pennsylvania
Jiao Yuan: University of Pennsylvania
Youyou Zhang: University of Pennsylvania
Xuepeng Wei: University of Pennsylvania
Nicki Loo: University of Pennsylvania
Yueying Wang: University of Pennsylvania
Yutian Pan: University of Pennsylvania
Tianli Zhang: University of Pennsylvania
Xiaomin Zhong: Zhongshan School of Medicine, Sun Yat-Sen University
Meixiao Long: Ohio State University
Kathleen T. Montone: University of Pennsylvania
Janos L. Tanyi: University of Pennsylvania
Yi Fan: University of Pennsylvania
Tian-Li Wang: Johns Hopkins University School of Medicine
Ie-Ming Shih: Johns Hopkins University School of Medicine
Xiaowen Hu: University of Pennsylvania
Lin Zhang: University of Pennsylvania

Nature Communications, 2019, vol. 10, issue 1, 1-17

Abstract: Abstract A growing emphasis in anticancer drug discovery efforts has been on targeting histone acetylation modulators. Here we comprehensively analyze the genomic alterations of the genes encoding histone acetylation modulator proteins (HAMPs) in the Cancer Genome Atlas cohort and observe that HAMPs have a high frequency of focal copy number alterations and recurrent mutations, whereas transcript fusions of HAMPs are relatively rare genomic events in common adult cancers. Collectively, 86.3% (63/73) of HAMPs have recurrent alterations in at least 1 cancer type and 16 HAMPs, including 9 understudied HAMPs, are identified as putative therapeutic targets across multiple cancer types. For example, the recurrent focal amplification of BRD9 is observed in 9 cancer types and genetic depletion of BRD9 inhibits tumor growth. Our systematic genomic analysis of HAMPs across a large-scale cancer specimen cohort may facilitate the identification and prioritization of potential drug targets and selection of suitable patients for precision treatment.

Date: 2019
References: Add references at CitEc
Citations:

Downloads: (external link)
https://www.nature.com/articles/s41467-019-08554-x Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:nat:natcom:v:10:y:2019:i:1:d:10.1038_s41467-019-08554-x

Ordering information: This journal article can be ordered from
https://www.nature.com/ncomms/

DOI: 10.1038/s41467-019-08554-x

Access Statistics for this article

Nature Communications is currently edited by Nathalie Le Bot, Enda Bergin and Fiona Gillespie

More articles in Nature Communications from Nature
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().